980 related articles for article (PubMed ID: 25501578)
1. Immune escape mechanisms as a guide for cancer immunotherapy.
Beatty GL; Gladney WL
Clin Cancer Res; 2015 Feb; 21(4):687-92. PubMed ID: 25501578
[TBL] [Abstract][Full Text] [Related]
2. [Cancer immunotherapy. Importance of overcoming immune suppression].
Malvicini M; Puchulo G; Matar P; Mazzolini G
Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
[TBL] [Abstract][Full Text] [Related]
3. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
5. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
6. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
7. The capacity of the immune system to control cancer.
Håkansson L
Eur J Cancer; 2009 Aug; 45(12):2068-70. PubMed ID: 19608409
[No Abstract] [Full Text] [Related]
8. The path to reactivation of antitumor immunity and checkpoint immunotherapy.
Kim HJ; Cantor H
Cancer Immunol Res; 2014 Oct; 2(10):926-36. PubMed ID: 25281320
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immune escape in the cancer immune cycle.
Tang S; Ning Q; Yang L; Mo Z; Tang S
Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
[TBL] [Abstract][Full Text] [Related]
10. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011.
Aptsiauri N; Cabrera T; Garcia-Lora A; Garrido F
Cancer Immunol Immunother; 2012 May; 61(5):739-45. PubMed ID: 22350069
[No Abstract] [Full Text] [Related]
11. [At the crossroads of cancer].
Chouaib S
Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599
[TBL] [Abstract][Full Text] [Related]
12. Acquired mechanisms of immune escape in cancer following immunotherapy.
Iorgulescu JB; Braun D; Oliveira G; Keskin DB; Wu CJ
Genome Med; 2018 Nov; 10(1):87. PubMed ID: 30466478
[TBL] [Abstract][Full Text] [Related]
13. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
14. CANCER IMMUNOLOGY. The "cancer immunogram".
Blank CU; Haanen JB; Ribas A; Schumacher TN
Science; 2016 May; 352(6286):658-60. PubMed ID: 27151852
[No Abstract] [Full Text] [Related]
15. Strategies of tumor immune evasion.
Seliger B
BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
[TBL] [Abstract][Full Text] [Related]
16. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
Messmer MN; Netherby CS; Banik D; Abrams SI
Cancer Immunol Immunother; 2015 Jan; 64(1):1-13. PubMed ID: 25432147
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of cancer: reprogramming tumor-immune crosstalk.
Payne KK; Toor AA; Wang XY; Manjili MH
Clin Dev Immunol; 2012; 2012():760965. PubMed ID: 23097673
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Pagès F; Bay JO; Tartour E
Bull Cancer; 2016 Nov; 103 Suppl 1():S119-S121. PubMed ID: 28057173
[No Abstract] [Full Text] [Related]
19. [The interplay of immunotherapy and chemotherapy, a novel approach].
Hanoteau A; Henin C; Moser M
Med Sci (Paris); 2016 Apr; 32(4):353-61. PubMed ID: 27137692
[TBL] [Abstract][Full Text] [Related]
20. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
